Compare · BMRA vs OSUR
BMRA vs OSUR
Side-by-side comparison of Biomerica Inc. (BMRA) and OraSure Technologies Inc. (OSUR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. BMRA focuses on Biotechnology: In Vitro & In Vivo Diagnostic Substances, while OSUR focuses on Medical/Dental Instruments.
- OSUR is the larger of the two at $248.6M, about 40.9x BMRA ($6.1M).
- OSUR has hit the wire 6 times in the past 4 weeks while BMRA has been quiet.
- OSUR has more recent analyst coverage (5 ratings vs 1 for BMRA).
- Company
- Biomerica Inc.
- OraSure Technologies Inc.
- Price
- -
- -
- Market cap
- $6.1M
- $248.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 0
- 6
- Recent ratings
- 1
- 5
Biomerica Inc.
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
OraSure Technologies Inc.
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company operates in two segments, Diagnostics and Molecular Solutions. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company's principal products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND services, a suite of genomic services. In addition, the company offers ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, infectious disease diagnostics, pharmacogenomics, personalized medicine, microbime, and animal genetics markets. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.
Latest BMRA
- SEC Form DEF 14A filed by Biomerica Inc.
- Biomerica Reports First Quarter Fiscal 2027 Financial Results
- SEC Form 10-Q filed by Biomerica Inc.
- SEC Form 8-K filed by Biomerica Inc.
- SEC Form EFFECT filed by Biomerica Inc.
- SEC Form EFFECT filed by Biomerica Inc.
- Amendment: SEC Form 10-K/A filed by Biomerica Inc.
- SEC Form S-3 filed by Biomerica Inc.
- SEC Form S-3 filed by Biomerica Inc.
- SEC Form 3 filed by new insider Qu Xiaoxuan
Latest OSUR
- Amendment: SEC Form 10-Q/A filed by OraSure Technologies Inc.
- SEC Form 10-Q filed by OraSure Technologies Inc.
- OraSure Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- OraSure Announces Third Quarter 2026 Financial Results; Strategic Execution Drives Double-Digit Year-Over-Year Growth and Margin Expansion
- Amendment: SEC Form SCHEDULE 13G/A filed by OraSure Technologies Inc.
- OraSure to Announce Third Quarter 2026 Financial Results and Host Earnings Call on November 9th
- Director Boyd Steven Kyle was granted 4,797 shares, increasing direct ownership by 3% to 168,031 units (SEC Form 4)
- Director Kenny John P. covered exercise/tax liability with 5,116 shares, decreasing direct ownership by 2% to 204,598 units (SEC Form 4)
- SEC Form S-8 filed by OraSure Technologies Inc.
- SEC Form 10-Q filed by OraSure Technologies Inc.